Endogenous prostaglandin E2 inhibits aberrant overgrowth of rheumatoid synovial tissue and the development of osteoclast activity through EP4 receptor

Arthritis and Rheumatism

Volumn 63, Issue 9, 2011, Pages 2595-2605

  Shibata Nozaki, Toshiko ^a   Ito, Hiroshi ^a   Mitomi, Hirofumi ^a   Akaogi, Jun ^a   Komagata, Tatsuya ^b   Kanaji, Toshiya ^b   Maruyama, Takayuki ^b   Mori, Toshihito ^c   Nomoto, So ^d   Ozaki, Shoichi ^a   Yamada, Hidehiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^d SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUTAPROST; CALCIUM PHOSPHATE; COLONY STIMULATING FACTOR 1; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GELATINASE B; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONAMIDE;

ARTICLE; CELL ACTIVITY; CULTURE MEDIUM; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATORY CELL; OSTEOCLAST; PANNUS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SUPERNATANT; SYNOVIUM; TISSUE CULTURE; TISSUE GROWTH; CELL CULTURE; DRUG EFFECT; METABOLISM; PATHOLOGY;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOMETHACIN; NITROBENZENES; OSTEOCLASTS; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SULFONAMIDES; SYNOVIAL MEMBRANE;

EID: 80052320267     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30428     Document Type: Article

References (67)

1. Mor A, Abramson SB, Pillinger MH,. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005; 115: 118-28. (Pubitemid 40693079)
2. Bromley M, Woolley DE,. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984; 27: 968-75. (Pubitemid 14004758)
3. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW,. Mononuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis? [review]. Arthritis Rheum 1997; 40: 5-18. (Pubitemid 27044031)
4. Danks L, Sabokbar A, Gundle R, Athanasou NA,. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 2002; 61: 916-21.
5. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 259-69. (Pubitemid 30395733)
6. Tsuboi H, Udagawa N, Hashimoto J, Yoshikawa H, Takahashi N, Ochi T,. Nurse-like cells from patients with rheumatoid arthritis support the survival of osteoclast precursors via macrophage colony-stimulating factor production. Arthritis Rheum 2005; 52: 3819-28. (Pubitemid 41798220)
7. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA,. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041-5.
8. Chikanza IC, Kingsley G, Panayi GS,. Peripheral blood and synovial fluid monocyte expression of interleukin 1α and 1β during active rheumatoid arthritis. J Rheumatol 1995; 22: 600-6.
9. Firestein GS, Xu WD, Townsend K, Broide D, Alvaro-Gracia J, Glasebrook A, et al. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 1988; 168: 1573-86. (Pubitemid 19023248)
10. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J,. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-8.
11. Feldmann M, Brennan FM, Maini RN,. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440. (Pubitemid 26130190)
12. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602. (Pubitemid 32162982)
13. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50. (Pubitemid 34620189)
14. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37. (Pubitemid 43122183)
15. Koch AE, Kunkel SL, Chensue SW, Haines GK, Strieter RM,. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 1992; 65: 23-9.
16. Cope AP, Maini RN,. Soluble tumor necrosis factor receptors in arthritis. J Rheumatol 1995; 22: 382-4.
17. Brennan FM, Chantry D, Turner M, Foxwell B, Maini R, Feldmann M,. Detection of transforming growth factor-β in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol 1990; 81: 278-85. (Pubitemid 20242535)
18. Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J,. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996; 39: 386-95. (Pubitemid 26085214)
19. Husby G, Bankhurst AD, Williams RC Jr,. Immunohistochemical localization of prostaglandin E in rheumatoid synovial tissues. Arthritis Rheum 1977; 20: 785-91.
20. Sturge RA, Yates DB, Gordon D, Franco M, Paul W, Bray A, et al. Prostaglandin production in arthritis. Ann Rheum Dis 1978; 37: 315-20. (Pubitemid 9017951)
21. 2 differentially modulates proinflammatory/ prodestructive effects of TNF-α on synovial fibroblasts via specific E prostanoid receptors/cAMP. J Immunol 2009; 183: 1328-36.
22. Akaogi J, Nozaki T, Satoh M, Yamada H,. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 2006; 6: 383-94. (Pubitemid 44941926)
23. 2. J Exp Med 1994; 180: 2365-70. (Pubitemid 24351620)
24. 2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181: 775-9.
25. 2 modulation of rheumatoid factor synthesis. Arthritis Rheum 1988; 31: 1473-80. (Pubitemid 19028413)
26. 2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J Immunol 1992; 148: 2845-52.
27. Zurier RB, Quagliata F,. Effect of prostaglandin E1 on adjuvant arthritis. Nature 1971; 234: 304-5.
28. 1 hybrid mice. II. Prevention of glomerulonephritis. Arthritis Rheum 1977; 20: 1449-56.
29. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002; 109: 883-93. (Pubitemid 34275109)
30. 2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 2010; 184: 7207-18.
31. Moriuchi-Murakami E, Yamada H, Ishii O, Kikukawa T, Igarashi R,. Treatment of established collagen induced arthritis with prostaglandin E1 incorporated in lipid microspheres. J Rheumatol 2000; 27: 2389-96.
32. Nozaki T, Takahashi K, Ishii O, Endo S, Hioki K, Mori T, et al. Development of an ex vivo cellular model of rheumatoid arthritis: critical role of CD14-positive monocyte/macrophages in the development of pannus tissue. Arthritis Rheum 2007; 56: 2875-85. (Pubitemid 47502733)
33. Yamamoto H, Maruyama T, Sakata K, Koketsu M, Kobayashi M, Yoshida H, et al. Novel four selective agonists for prostaglandin E receptor subtypes. Prostaglandins Other Lipid Mediat 1999; 59: 150.
34. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000; 141: 1554-9. (Pubitemid 32269125)
35. 2 in chondrocyte differentiation. Osteoarthritis Cartilage 2003; 11: 644-52. (Pubitemid 37045683)
36. Jones RL, Qian YM, Chan KM, Yim AP,. Characterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br J Pharmacol 1998; 125: 1288-96. (Pubitemid 28542539)
37. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
38. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-46.
39. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
40. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995; 38: 1581-8.
41. Van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC,. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1097-106.
42. Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G,. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 2004; 199: 244-51. (Pubitemid 38436751)
43. Bromley M, Woolley DE,. Histopathology of the rheumatoid lesion: identification of cell types at sites of cartilage erosion. Arthritis Rheum 1984; 27: 857-63. (Pubitemid 14067780)
44. Feldmann M, Maini RN,. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96. (Pubitemid 32368033)
45. 2: role of early growth response protein-1 (Egr-1). Osteoarthritis Cartilage 1999; 7: 395-8. (Pubitemid 29331559)
46. 2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277: 44147-54. (Pubitemid 36157844)
47. 2 dissociates nuclear trafficking of individual NF-κB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J Immunol 2005; 175: 6924-30. (Pubitemid 41598938)
48. 2-dependent transcriptional suppression of cytokine-induced tumor necrosis factor-α gene expression in human macrophages and rheumatoid arthritis-affected synovial fibroblasts. J Biol Chem 2005; 280: 9536-46. (Pubitemid 40409649)
49. 2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003; 278: 12151-6. (Pubitemid 36800194)
50. Minami M, Shimizu K, Okamoto Y, Folco E, Ilasaca ML, Feinberg MW, et al. Prostaglandin E receptor type 4-associated protein interacts directly with NF-κB1 and attenuates macrophage activation. J Biol Chem 2008; 283: 9692-703.
51. Bartok B, Firestein GS,. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-55.
52. Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, et al. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol 2003; 171: 6080-9. (Pubitemid 37467229)
53. Barnes PJ, Karin M,. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71. (Pubitemid 27163860)
54. Brown KD, Claudio E, Siebenlist U,. The roles of the classical and alternative nuclear factor-κB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008; 10: 212.
55. 2 upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 2000; 272: 744-8. (Pubitemid 30420710)
56. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-86.
57. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA,. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32: 1-7. (Pubitemid 36173806)
58. 2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000; 275: 19819-23. (Pubitemid 30441583)
59. Sakuma Y, Tanaka K, Suda M, Komatsu Y, Yasoda A, Miura M, et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect Immun 2000; 68: 6819-25. (Pubitemid 32463389)
60. Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 2000; 15: 218-27. (Pubitemid 30095708)
61. 2, interleukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998; 139: 3157-64. (Pubitemid 28512345)
62. 2 strongly inhibits human osteoclast formation. Endocrinology 2005; 146: 5204-14. (Pubitemid 41653034)
63. Graham S, Gamie Z, Polyzois I, Narvani AA, Tzafetta K, Tsiridis E, et al. Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: in vivo and in vitro evidence. Expert Opin Investig Drugs 2009; 18: 746-66.
64. Nakagawa K, Imai Y, Ohta Y, Takaoka K,. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 2007; 41: 543-8. (Pubitemid 47385438)
65. 2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 2004; 34: 940-8. (Pubitemid 38749231)
66. Clarris BJ,. Morphological effects of prostaglandins E1, E2 and F2α on fibroblast-like cultures of human synovial cells. Experientia 1982; 38: 350-1. (Pubitemid 12075705)
67. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S,. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997; 122: 217-24. (Pubitemid 27397191)